<DOC>
	<DOC>NCT01078714</DOC>
	<brief_summary>The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism</brief_summary>
	<brief_title>Efficiency of Bumetanide in Autistic Children</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Bumetanide</mesh_term>
	<criteria>Children from 3 to 10 years old, answering the diagnosis of typical autism according to the diagnostic criteria of autism of the classification of the WHO ( CIM10) and the parents of which gave a free, enlightened and written consent. Patients epileptic autistics treated by anticomitiaux or having hurts of the central nervous system Patients autistics receiving a psychotropic treatment Patients presenting disorders electrolytes Patients presenting a hypersensibility known about sulpha drugs Presenting patients against indications relative to the treatment by bumetanide Patients already treated by diuretics Patients presenting a hepatic or renal incapacity Patients presenting an elongation of the QT to the electrocardiogram. Patients autistics of CARS sore is lower than 30.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Autism</keyword>
	<keyword>Bumetanide</keyword>
	<keyword>GABA</keyword>
	<keyword>NKCC1</keyword>
</DOC>